Notably, the use of anti-IL-6 therapy and/or corticosteroids for the management of CRS (usually following CAR T cell expansion) has not negatively affected disease-free survival outcomes in larger cohorts107,108. This evidence concerns the gene IL6 and congenital rubella syndrome.